The company generated consumer sales of $13.6bn last year, an increase of 2.2% compared with 2016
Johnson & Johnson has revealed it generated global consumer sales of US$13.6bn in 2017, up 2.2% on the year before.
The results, excluding the net impact of acquisitions and divestitures, were negatively impacted by declines in the baby care and oral care businesses, which includes Johnson’s Baby and Listerine.
However Neutrogena helped lift sales, along with over-the-counter paracetamol products including Tylenol.
Overall, including its pharmaceutical business, Johnson & Johnson made sales of $76.5bn for the full year, up 6.3% versus 2016.
Alex Gorsky, Chairman and CEO, said: “Johnson & Johnson delivered strong adjusted earnings per share growth of 8.5% and total shareholder return of greater than 24% in 2017, driven by the robust performance of our Pharmaceutical business, while continuing to make investments in acquisitions, innovation and strategic partnerships to accelerate growth in each of our businesses.
“As we enter 2018 and look beyond, we are experiencing an incredible pace of change in health care.
“Johnson & Johnson is uniquely positioned to lead during this dynamic era and deliver innovative solutions for patients and consumers that drive sustainable, long-term growth.
“We are pleased with the passage of recent legislation modernising the US tax system, which enables Johnson & Johnson to invest in innovation at higher levels to help address the most challenging unmet medical needs facing health care today.”